Teva Pharmaceutical Industries Ltd., a largest generic pharmaceutical company, reported that the U. S. Food and Drug Administration (FDA) has approved the company's ANDA for Mupirocin ointment USP, 2 per cent. Shipment of the product will begin immediately.
Mupirocin ointment USP, 2 per cent is the AB-rated generic equivalent of GlaxoSmithKline's Bactroban ointment, a topical antibacterial for treatment of impetigo. Annual sales of the brand product are approximately $97 million.